Classification of Hyperlipidemia Flashcards
Frederickson Classification
I: seen in young children; chylomicrons are involved
V: seen in adults; IDL (chylomicrons and VLDL remnants)
2b and 4 are most common
2a = familial hyperlipidemia
Type I Hyperlipidemia
Chylomicronemia - very rare
Most of these children do not live/live long
Causes: Lipoprotein Lipase Deficiency
Present in early childhood with chronic abdominal pain, recurrent pancreatitis, and hepato-splenomegaly
Eruptive xanthomas on extremities and trunk
Can develop diabetes later due to the chronic pancreatitis and the inflammatory destruction of the beta cells
Functions of LPL
LPL is a water soluble enzyme attached to the luminal surface of small capillaries in muscle and adipose tissue
LPL hydrolyzes the TG’s in chylomicrons and VLDL and converts them into free fatty acids (FFA’s) and glycerol
LPL also promotes hepatic uptake (post-meal clearance) of chylomicron remnants, cholesterol-rich lipoproteins, and FFA
LPL requiresApoC-IIas a cofactor
No enzyme, then serum looks milky and fatty
Serum chylomicrons are present & triglycerides (TG’s) are extremely elevated; 2,000-12,000 mg/dl
Foam cells laden with lipids can be seen in liver, spleen, and bone marrow on biopsy
Treatment of LPL Deficiency
In Type I Hyperlipidemia
No effective medications
Severe fat restriction:
Familial Hypercholesterolemia (FH)
Type IIa Hyperlipidemia
Abnormalities in LDL Receptor Function
FH1—LDL receptor defects (5 forms)
FH2—Apo B-100 abnormalities causing decreased LDL uptake, and HMG-CoA reductase is turn on all the time to induce production of endogenous cholesterol (aka loss of negative feedback inhibition)
ApoB = LDL association aka BAD ApoA = HDL association aka good
Phenotypes of FH (Type IIa)
Homozygote:
- 55 % reduction in LDL clearance
- serum LDL’s of 400-800 mg/d
- Premature CAD in teens-20’s
Heterozygote:
- 27 % reduction in LDL clearance
- serum LDL’s of 260-400 mg/dl
- Premature CAD in late 20’s-30”s
Clinical Features of FH
Tendenous Xanthomas: achilles and patellar tendons
Arcus Cornea
Premature CAD
Treatment of FH
LDL lowering with HMG-CoA reductase inhibitors (statins) has improved outcomes in heterozygote form but minor effect in homozygotes
PKCS9 antagonists were just FDA approved this year and are the most potent LDL reducing medications ever developed
Aphoresis of LDL particles q 2 weeks can be performed if patients do not respond to lipid-lowering medications and most homozygote patients require it
Liver Transplant: works, but need donor
Combined Hyperlipidemia(Type IIb)
- Familial Form (FCH): Polygenetic decreases in LDL receptor or Apo B function
- Acquired Form (McDonald’s form): Visceral obesity and insulin resistance
Acquired Form Type IIb
“ The Metabolic Syndrome” Visceral obesity Glucose intolerance “Dyslipidemia” Insulin resistance Hypertension
Familial Combined Hyperlipidemia Phenotypes
- Elevated LDL and VLDL and ApoB
- Elevated TG and VLDL from hepatic over-production
- Impaired uptake of exogenous lipids from the diet
Xanthomas of Eye Lid and Heels of Familial Combined Hyperlipidemia
Treatment of Familial Combined Hyperlipidemia
Aggressive lipid-lowering with combinations of HMG-Co-A Reductase Inhibitors, Fibrates, and Nicotinic Acid
Familial Dysbeta-Lipoproteinemia(Type III Hyperlipidemia)
Abnormal Apo E2 isoforms
ApoE is present to effect hepatocyte uptake of TG
Palmar xanthomas
Orange colored skin from deposition of carotenoids
Dx: Using lipoprotein electrophoresis the remnant lipoproteins accumulate as a “broad β” band
Familial Hypertriglyceridemia(Type IV)
Polymorphisms of the apo A-I/C-III and the insulin gene (insulin resistance)
Second most common
Clinical picture may be similar to Type IIb…. but LDL is not as high; cannot really tell between IIb and IV
Very high VLDL and low HDL with elevated LDL and TG’s
Small dense LDL particles
Type V Hyperlipidemia
Mixed Hyperlipidemia
Mutations of the APOA5 gene
Between bouts of acute decompensation: look like type II diabetic with Type IV hyperlipidemia
“Acquired LPL Deficiency”